Lucky Games nuvarande mål är att inleda nästa fas i sin tillväxtstrategi där vi ser utrymme för en f...
Redeye comments on Energy Save’s Q3 23/24 report, which presented sequential growth but higher costs...
Redeye gives its view on yesterday's press release from Genovis' which stated that the deal between ...
Lyckegård Group AB (”Lyckegård” eller ”bolaget”) meddelade den 13 mars år 2024 att bolaget har ingåt...
Systemair redovisade en rapport som fick ovanligt stor negativ reaktion på aktiemarknaden.
Redeye embraces the FDA clearance for the trauma indication using CERAMENT G in the US.
Biovica’s sales from clinical use of DiviTum tests are up 350% in Q3 compared with the first half, a...
Mangold uppdaterar cybersäkerhetsbolaget Cyber Security 1 ("CYBER1") efter det fjärde kvartalet 2023...
Ljummet kvartal med vissa ljusglimtar Gullberg & Jansson levererade en svagare avslutning på året.
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent annual rep...
Redeye retains its Base Case and 2025 forecasts despite the softer short-term outlook in the newly a...
Skointegrering långsiktig möjlighet för att accelerera tillväxt Björn Borg har meddelat att man avse...
Lägre tillväxt men bättre marginal och kassaflöde än väntat, leder till att kassan bör räcka och där...
Mendus is forging ahead with vididencel, its primary clinical asset, aiming to address a market nich...
- SEK 465m in two orders for Intercom and Vehicle radios.
Redeye comments on Invisio’s announced order regarding Intercom systems with a value of SEK230m whic...
Redeye is encouraged by Fluoguide delivering on its promises by entering a collaboration in head and...
Redeye holds a favourable view on Kontigo Care’s proposed, directed share issue of around SEK10.
Redeye takes a positive stance towards Speqta’s direct share issue despite somewhat lowering its Bas...
Biovica, active in blood-based cancer monitoring, has signed a master service agreement, enabling Bi...
